2.1. General To evaluate the efficacy and safety of a Cannabis sativa extract (CBD (Cannabidiol) + up to 0.3% THC (Delta-9-tetrahydrocannabinol)), compared to placebo, in the treatment of cocaine/crack use disorder. 2.2. Specifics * Compare the amount and frequency of cocaine use between the group treated with Cannabis sativa extract and the placebo group * Compare adherence to treatment between the group treated with Cannabis sativa extract and the placebo group * Evaluate the prevalence and intensity of depressive and anxious symptoms in patients using Cannabis sativa extract compared to patients using placebo * Evaluate the incidence and severity of side effects in the active group compared to placebo.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Efficacy of the extract of cannabis compared to placebo
Timeframe: biweekly